ICAAC to Feature Higher Cure Rate Options for Hepatitis C

New therapeutic regimens are in the works to permanently curb many hepatitis C infections. Delegates attending the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) will be privy to the latest, cutting-edge information.

"There will be a symposium on what every infectious disease physician should know about treating hepatitis C," Robin Patel, MD, vice chair of the ICAAC program committee, told Medscape Medical News.